197 related articles for article (PubMed ID: 38129234)
1. Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy.
Hashimoto M; Ramalingam SS; Ahmed R
Trends Cancer; 2024 Apr; 10(4):332-346. PubMed ID: 38129234
[TBL] [Abstract][Full Text] [Related]
2. PD-1 combination therapy with IL-2 modifies CD8
Hashimoto M; Araki K; Cardenas MA; Li P; Jadhav RR; Kissick HT; Hudson WH; McGuire DJ; Obeng RC; Wieland A; Lee J; McManus DT; Ross JL; Im SJ; Lee J; Lin JX; Hu B; West EE; Scharer CD; Freeman GJ; Sharpe AH; Ramalingam SS; Pellerin A; Teichgräber V; Greenleaf WJ; Klein C; Goronzy JJ; Umaña P; Leonard WJ; Smith KA; Ahmed R
Nature; 2022 Oct; 610(7930):173-181. PubMed ID: 36171288
[TBL] [Abstract][Full Text] [Related]
3. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8
Codarri Deak L; Nicolini V; Hashimoto M; Karagianni M; Schwalie PC; Lauener L; Varypataki EM; Richard M; Bommer E; Sam J; Joller S; Perro M; Cremasco F; Kunz L; Yanguez E; Hüsser T; Schlenker R; Mariani M; Tosevski V; Herter S; Bacac M; Waldhauer I; Colombetti S; Gueripel X; Wullschleger S; Tichet M; Hanahan D; Kissick HT; Leclair S; Freimoser-Grundschober A; Seeber S; Teichgräber V; Ahmed R; Klein C; Umaña P
Nature; 2022 Oct; 610(7930):161-172. PubMed ID: 36171284
[TBL] [Abstract][Full Text] [Related]
4. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
Front Immunol; 2020; 11():7. PubMed ID: 32117218
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-10 receptor signaling promotes the maintenance of a PD-1
Hanna BS; Llaó-Cid L; Iskar M; Roessner PM; Klett LC; Wong JKL; Paul Y; Ioannou N; Öztürk S; Mack N; Kalter V; Colomer D; Campo E; Bloehdorn J; Stilgenbauer S; Dietrich S; Schmidt M; Gabriel R; Rippe K; Feuerer M; Ramsay AG; Lichter P; Zapatka M; Seiffert M
Immunity; 2021 Dec; 54(12):2825-2841.e10. PubMed ID: 34879221
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.
West EE; Jin HT; Rasheed AU; Penaloza-Macmaster P; Ha SJ; Tan WG; Youngblood B; Freeman GJ; Smith KA; Ahmed R
J Clin Invest; 2013 Jun; 123(6):2604-15. PubMed ID: 23676462
[TBL] [Abstract][Full Text] [Related]
7. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
[TBL] [Abstract][Full Text] [Related]
8. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
9. Functional HPV-specific PD-1
Eberhardt CS; Kissick HT; Patel MR; Cardenas MA; Prokhnevska N; Obeng RC; Nasti TH; Griffith CC; Im SJ; Wang X; Shin DM; Carrington M; Chen ZG; Sidney J; Sette A; Saba NF; Wieland A; Ahmed R
Nature; 2021 Sep; 597(7875):279-284. PubMed ID: 34471285
[TBL] [Abstract][Full Text] [Related]
10. Cytokine-Mediated Regulation of CD8 T-Cell Responses During Acute and Chronic Viral Infection.
Hashimoto M; Im SJ; Araki K; Ahmed R
Cold Spring Harb Perspect Biol; 2019 Jan; 11(1):. PubMed ID: 29101105
[TBL] [Abstract][Full Text] [Related]
11. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions.
Hashimoto M; Kamphorst AO; Im SJ; Kissick HT; Pillai RN; Ramalingam SS; Araki K; Ahmed R
Annu Rev Med; 2018 Jan; 69():301-318. PubMed ID: 29414259
[TBL] [Abstract][Full Text] [Related]
12. TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision.
Chen Z; Ji Z; Ngiow SF; Manne S; Cai Z; Huang AC; Johnson J; Staupe RP; Bengsch B; Xu C; Yu S; Kurachi M; Herati RS; Vella LA; Baxter AE; Wu JE; Khan O; Beltra JC; Giles JR; Stelekati E; McLane LM; Lau CW; Yang X; Berger SL; Vahedi G; Ji H; Wherry EJ
Immunity; 2019 Nov; 51(5):840-855.e5. PubMed ID: 31606264
[TBL] [Abstract][Full Text] [Related]
13. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
Front Immunol; 2021; 12():648420. PubMed ID: 34589081
[TBL] [Abstract][Full Text] [Related]
14. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.
Im SJ; Hashimoto M; Gerner MY; Lee J; Kissick HT; Burger MC; Shan Q; Hale JS; Lee J; Nasti TH; Sharpe AH; Freeman GJ; Germain RN; Nakaya HI; Xue HH; Ahmed R
Nature; 2016 Sep; 537(7620):417-421. PubMed ID: 27501248
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade.
Jadhav RR; Im SJ; Hu B; Hashimoto M; Li P; Lin JX; Leonard WJ; Greenleaf WJ; Ahmed R; Goronzy JJ
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):14113-14118. PubMed ID: 31227606
[TBL] [Abstract][Full Text] [Related]
16. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
17. Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help.
Monjazeb AM; Tietze JK; Grossenbacher SK; Hsiao HH; Zamora AE; Mirsoian A; Koehn B; Blazar BR; Weiss JM; Wiltrout RH; Sckisel GD; Murphy WJ
PLoS One; 2014; 9(8):e102709. PubMed ID: 25119341
[TBL] [Abstract][Full Text] [Related]
18. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells.
Odorizzi PM; Pauken KE; Paley MA; Sharpe A; Wherry EJ
J Exp Med; 2015 Jun; 212(7):1125-37. PubMed ID: 26034050
[TBL] [Abstract][Full Text] [Related]
19. Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C.
Osuch S; Laskus T; Berak H; Perlejewski K; Metzner KJ; Paciorek M; Radkowski M; Caraballo Cortés K
Sci Rep; 2020 Sep; 10(1):16060. PubMed ID: 32994477
[TBL] [Abstract][Full Text] [Related]
20. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]